Metraipolis › archive › dc_f159f35e37ec

GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome — Europe PMC PMID:42032706

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42032706
DOI
10.1186/s40478-[numero omesso]-y
License (as archived)
solo-consultazione
Archived
2026-11-01T07:48:54.004Z
SHA-256 of the archived text
76f3379f9f4d11d29d304a09a566e230dee6aaa6a2d1673e90be3fd4a800b330
Stable URL of this page
https://metraipolis.com/documento/dc_f159f35e37ec

How to cite

GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome — Europe PMC PMID:42032706 — Europe PMC (en), https://europepmc.org/article/MED/42032706 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f159f35e37ec (Metraipolis archive dc_f159f35e37ec, sha256 76f3379f9f4d11d29d304a09a566e230dee6aaa6a2d1673e90be3fd4a800b330)
BibTeX
@misc{dcf159f35e37ec,
  title = {GFAP degradation in TBI: linking novel modified products to astrocyte pathology and patient outcome — Europe PMC PMID:42032706},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42032706},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f159f35e37ec; sha256 76f3379f9f4d11d29d304a09a566e230dee6aaa6a2d1673e90be3fd4a800b330},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42032706. Agents can read the archived copy with the MCP tool read_document.